Mar 5, 2024

“Migraine Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the 7MM. DelveInsight’s “Migraine Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Migraine market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Migraine Market Forecast Some of the key facts of the Migraine Market Report: The Migraine market size is anticipated to grow with a significant CAGR during the study period (2019-2032) All participants who had a headache within the previous 12 months prior to the survey between October 2019 and March 2020 were included in the BURDEN 2020 study, which was developed by the RKI and conducted by the market and social research institute USUMA GmbH. According to the survey, 40.4% of men and 57.5% of women reported having headaches in the previous 12 months. In both men and women, 6.0% and 1.2%, respectively, suffered from migraines Migraine is the most prevalent neurological condition, according to German research community funding headache research in Essen 2021. Around 14% of German women and 8% of German men are affected. About 2% of people have a chronic form of the condition Key Migraine Companies: Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie, Tian Medical Inc., Allergan, Eli Lilly and Company, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others Key Migraine Therapies: AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others The Migraine epidemiology based on gender analyzed that the prevalence of migraine in female is slightly higher than male The Migraine market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics. Migraine Overview Migraine, a main headache illness, is a neurological condition that commonly manifests as severe, incapacitating headaches among other symptoms. It affects all ages and frequently runs in families. There are primarily two types: acute migraine and Migraine. Migraine Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Migraine market or expected to get launched during the study period. The analysis covers Migraine market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Migraine Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Migraine Companies: Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie, Tian Medical Inc., Allergan, Eli Lilly and Company, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others Key Migraine Therapies: AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies Migraine Market Dynamics: Migraine market drivers and Migraine market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies Migraine Unmet Needs, KOL’s views, Analyst’s views, Migraine Market Access and Reimbursement